

ASX ANNOUNCEMENT

Share Purchase Plan Results

20th April 2016: Analytica Ltd (ASX: ALT). The Company is pleased to announce that the Share Purchase Plan was well supported by shareholders with \$567,700 being received. 222,627,485 shares at \$0.00255 will be allotted today. Following allotment of these shares ALT will have issued capital of 1,630,197,395 shares.

The SPP forms part of the Company's current fund raising initiatives which are comprised of:

- A private placement of \$280k (\$0.00255 cents per share) to non-related parties on the 21st March (previously announced).
- A placement to the Chairman, Dr Michael Monsour, of \$1m at \$0.03 cents per share. This placement is subject to shareholder approval at an Extraordinary General Meeting to be held on Friday 22nd April 2016 and
- A placement of approximately \$500k to a new cornerstone investor subject to shareholder approval of the placement to Dr Michael Monsour.

Following the completion of these fund raising initiatives the company will have raised approximately \$2.4m.

These fund raisings, along with expenditure reduction initiatives announced on the 10th March 2016 has placed the Company on a solid foundation.

The Company wishes to thank shareholders for their support of the Company.

Dr Michael Monsour
Chairman

For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

Follow us on:



About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to PeriCloud where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition.

PeriCoach has regulatory clearance in Australia, and has CE mark and USFDA 510(k) clearance. The product is available for sale in Australia and New Zealand, UK and Ireland, and in the USA by prescription.

